Rana Tahbaz

TL;DR: These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2019 and are thoroughly evaluated to establish international standards for the care of kidney cancer patients.

TL;DR: The European Association of Urology (EAU) Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC as discussed by the authors .

TL;DR: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve).

TL;DR: The randomised phase III clinical trial Checkmate-214 showed a survival superiority for the combination of ipilimumab and nivolumab when compared with the previous standard of care in first-line metastatic/advanced clear cell renal cell carcinoma (RCC) and the European Association of Urology RCC guidelines have been updated.

TL;DR: A systematic review and meta-analysis of relevant literature comparing the oncological outcomes and adverse events of different systemic therapies for patients with metastatic non-ccRCC suggested that a drug called sunitinib might be more effective than everolimus, but the statistics supporting this statement are not yet entirely reliable.